In 2023, the European market for Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) medicines exhibited variety across countries. Spain led with the highest sales at 889.8 million USD PPP, followed by Germany at 761.1 million. Contrasting changes were noted; Spain's sales increased by 4.61%, while Germany observed a decline of 4.01%. Greece saw a significant drop of 5.25%, whereas Denmark reported a rise of 5.81%. Austria experienced the largest decrease at 8.61%.
Looking ahead, the European market's trajectory will hinge on emerging healthcare policies, medical advancements, and demographic shifts. Continuous growth may be expected in regions embracing innovation and investment in healthcare infrastructure.
- Spain: 4.61% increase
- Germany: 4.01% decrease
- Croatia: 2.5% increase
- Greece: 5.25% decrease
- Czech Republic: 0.82% increase
- Norway: 1.58% increase
- Austria: 8.61% decrease
- Denmark: 5.81% increase
- Slovakia: 3.22% increase
- Slovenia: 1.25% increase
- Iceland: 4.65% increase
Top countries in Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) Medicine Sales by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Spain | 889.8 | 2023 | +0.88% | +4.61% | View data |
| 2 | 2 Germany | 761.1 | 2023 | -3.06% | -4.01% | View data |
| 3 | 3 Croatia | 314 | 2023 | +1.95% | +2.5% | View data |
| 4 | 4 Greece | 203.7 | 2023 | -8.94% | -5.25% | View data |
| 5 | 5 Czech Republic | 65.3 | 2023 | +2.03% | +0.82% | View data |
| 6 | 6 Norway | 37.1 | 2023 | -1.59% | +1.58% | View data |
| 7 | 7 Austria | 29.2 | 2023 | -15.36% | -8.61% | View data |
| 8 | 8 Denmark | 25.6 | 2023 | -1.92% | +5.81% | View data |
| 9 | 9 Slovakia | 23.9 | 2023 | +2.14% | +3.22% | View data |
| 10 | 10 Slovenia | 18.3 | 2023 | -1.61% | +1.25% | View data |
